Compare AEVA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | CADL |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2021 |
| Metric | AEVA | CADL |
|---|---|---|
| Price | $14.28 | $10.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $30.00 | $21.75 |
| AVG Volume (30 Days) | ★ 1.2M | 979.5K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.53 | ★ 58.62 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | $78.97 | N/A |
| Revenue Next Year | $124.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.83 | $4.35 |
| 52 Week High | $31.30 | $14.00 |
| Indicator | AEVA | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 40.32 |
| Support Level | $13.95 | $9.40 |
| Resistance Level | $14.30 | $10.59 |
| Average True Range (ATR) | 0.81 | 0.67 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 11.26 | 7.71 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.